Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 years or older
• People who have been diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to previous treatment, according to specific medical guidelines
• People whose cancer has spread to lymph nodes 10 cm or larger in size may need special approval from the trial sponsor before being considered (confirm with trial site)
• People whose general physical functioning is rated as 0 or 1 on a standard medical scale, meaning they are fully active or have only minor restrictions on physically strenuous activity
• People whose heart electrical activity (measured by a specific heart test called an ECG) falls within an acceptable range for their sex
• People whose bone marrow, kidneys, and liver are functioning well enough without the need for special support treatments
• People who are willing to use effective contraception throughout the treatment period and for at least three months after the last dose
• Women who could become pregnant must have a negative pregnancy test within 14 days before starting the trial drug
• Male participants must agree not to donate sperm during treatment and for at least three months after the last dose
• People who are able to understand and sign a written consent form before any trial procedures begin
• People who are willing and able to follow all trial procedures and attend follow-up appointments

Who may not be able to join:

• People who have had a donor stem cell transplant at any time, a cell-based immune therapy within the past 24 months, or their own stem cells transplanted back within the past 12 months
• People who have received a specific type of antibody therapy targeting CLL within 4 weeks before the first trial dose
• People who have received anti-cancer treatments (such as chemotherapy, radiation, steroids for cancer, certain herbal cancer medicines, or investigational drugs) within 14 days or a set number of half-lives of those drugs before the first dose, or who still have significant side effects from previous treatments that have not sufficiently resolved
• People who have taken certain medications that affect how the body processes drugs (specific CYP3A inhibitors or inducers, such as fluconazole, ketoconazole, clarithromycin, rifampin, carbamazepine, phenytoin, or St. John's wort) within 14 days before the first dose
• People who have not sufficiently recovered from a surgical procedure, or who have had major surgery within 28 days or minor surgery within 14 days before starting the trial
• People who have previously been treated with a type of drug called a Bcl-2 inhibitor
• People whose CLL/SLL has transformed into a more aggressive lymphoma or has spread to the brain or spinal cord
• People with moderate or severe heart disease (Grade 2 or higher by a standard heart classification system)
• People with a significant history of serious kidney, nerve, psychiatric, lung, hormonal, immune, heart, or liver disease that the trial doctor believes could be made worse by participating
• People who require blood-thinning medications such as warfarin or similar anticoagulants
• People who are known to be allergic to the trial drug or similar substances
• People who are pregnant, breastfeeding, or planning to become pregnant during the trial or within 3 months after the last dose
• People who have had another active cancer (other than CLL/SLL) within the 3 years before joining, with some exceptions such as fully treated early-stage cervical cancer, completely removed skin cancers, or previously cured cancers that have been fully treated
• People who have a condition that prevents them from properly absorbing oral medications
• People with uncontrolled serious infections (including certain hepatitis B, hepatitis C, or HIV infections) or who have had a fever with very low white blood cell counts within the week before starting the trial
• People with active and uncontrolled autoimmune conditions affecting blood cells, such as autoimmune hemolytic anemia or immune thrombocytopenia
• People who have any other condition that the trial doctor believes would make participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.